Objective:
To evaluate the early results of indigenously developed decellularised porcine xenograft conduit for RVOT reconstruction in patients with congenital heart disease.

Methods and Results:
Prior to clinical use the xenograft was subjected to extensive tests to ensure preservation of collagen structure and tissue strength. Clinical use was initiated in February 2006. Till date this xenograft has been implanted in 46 patients (aged 5months to 29 years, mean-8.9 years) with congenital heart disease. The clinical conditions encountered were TOF with pulmonary atresia (n=23) or pulmonary stenosis (n=6) or absent pulmonary valve (n=4); truncus arteriosus (n=2); DORV with VSD and pulmonary stenosis or atresia (n=7); TGA with left ventricular outflow tract obstruction (n=2); homograft replacement (n=1) and right ventricular outflow tract reconstruction following tetralogy repair (n=1). The median xenograft size used was 16mm (range 13-23mm). Follow up was complete for all domestic patients (n=20) and ranged from 3-18 months. There was no incidence of conduit thrombosis, one patient developed infective endocarditis after one month of surgery and was managed conservatively. One patient required conduit replacement five months after truncus repair. Among the remaining survivors xenograft function was excellent in the majority of patients. Mild to moderate obstruction was noted at the distal end of the conduit in two patients and mild to moderate regurgitation was seen in four patients. There seemed to be no progress of pulmonary regurgitation on serial follow up.

Conclusions:
Indigenously developed decellularised xenograft offers excellent hemodynamics with a low re-operation rate in the short term follow up.